Novo Nordisk A/S maintained its leading position for glucagon-like peptide-1 (GLP-1) diabetes medicines with a 52.7% global market share in 2021, up by 2.3 percentage points from a year earlier. Novo's portfolio consists of just three GLP-1 medicines, but together they generated 38% of the company's sales. Group sales were DKK 140.8 billion ($21.4 billion) in 2021, an increase of 11% from a year earlier. The GLP-1 medicines generated DKK 53.6 billion, while insulins produced revenue of DKK 56 billion.
